Compare Bristol-Myers Squibb Co (BMY) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs KraneShares CSI China Internet ETF — how do they compare? Bristol-Myers Squibb Co trades at $57.56 (market cap $116.30B), while KraneShares CSI China Internet ETF trades at $26.78. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while KraneShares CSI China Internet ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| BMY | KWEB | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $42.94 |
52-Week Low | $42.60 | $23.63 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
KWEB trades at $26.23, down 0.57% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF provides exposure to Chinese internet and AI companies, benefiting from government support and AI-driven growth, though key financial ratios are unavailable. Recent news highlights China's push for tech self-reliance and strong export performance.
Outlook is mixed: AI expansion and attractive valuations offer upside, but geopolitical tensions and regulatory risks pose challenges. The stock's performance hinges on China's economic policies and global tech competition, requiring careful risk assessment for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
